Navigation Links
GlaxoSmithKline Accelerates Review of Exelixis' XL880
Date:8/23/2007

XL880 has attractive pharmaceutical properties, with high solubility and oral bioavailability. In preclinical studies, XL880 inhibited its targets with nanomolar potency, and retained potent activity against mutationally activated forms of MET found in hereditary papillary renal cell carcinomas. The compound also demonstrated dose-dependent tumor growth inhibition in models of breast cancer, colorectal cancer, non-small cell lung cancer, and glioblastoma, and has been shown to cause substantial tumor regression in all models tested. Significantly, a single dose of XL880 completely inhibited tumor growth for 21 days in a glioblastoma model.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in Phase 2 and Phase 1 clinical development for cancer and renal disease. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GSK, Bristol-Myers Squibb, Genentech, Wyeth Pharmaceuticals and Daiichi-Sankyo. For more information, please visit the company's web site at http://www.exelixis.com.

This press release contains forward-looking statements, including, without limitation, statements related to the future development and potential efficacy of XL880 and the timing of the submission of XL880 to GSK. Words such as "expects," "will," "expedite," "believe" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Exelixis' current expectations. Forward-looking statements involve risks and u
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. GlaxoSmithKline and Genmab Present Positive Phase II Results With ofatumumab in Patients With Rheumatoid Arthritis (RA)
2. GlaxoSmithKline’s Hib-MenCY-TT Combination Vaccine Meets Phase II Study Endpoints of Immunogenicity and Safety Compared to Licensed Vaccines
3. New Data on Genmab and GlaxoSmithKlines Ofatumumab: Phase II Study in Rheumatoid Arthritis to be Presented at EULAR
4. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
5. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
6. Neuroblastoma Expert Reviews Progress and Challenges in Fighting Difficult Pediatric Cancer
7. Medicures MEND-CABG Trial Results Published in Peer Reviewed Journal
8. Review of Nexavar Data Presented at ASCO 2007- Investor Conference Call on June 4, 2007
9. Salix Pharmaceuticals Previews Digestive Disease Week 2007
10. Reatas Synthetic Triterpenoids Profiled in Nature Reviews Cancer
11. CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014 Aileron ... Summary Global Markets Direct,s, ,Aileron Therapeutics, ... an overview of the Aileron Therapeutics, Inc.,s pharmaceutical ... comprehensive information on the current therapeutic developmental pipeline ... at various stages, therapeutics assessment by drug target, ...
(Date:9/30/2014)... -- According to their CEO, Rob Bohacs ... going through a complete transformation with highly targeted ... current clinical trial management process isn,t configured to ... which will ultimately drive the prescription cancer drugs ... been recognized by the National Cancer Institute as an ...
(Date:9/30/2014)... LOS ANGELES , Sept. 30, 2014   ... apnea shopping destination , today announced that it now ... ResMed . AirSense CPAPs are the first sleep apnea ... makes it simple and easy to track and share ... the overall effectiveness of their CPAP therapy.  In addition, ...
Breaking Medicine Technology:Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 2Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 3Small Denver Company Pharmatech driving a large revolution in how cancer clinical trials are managed 2Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 2Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 3Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 4
... Dec. 6, 2011 Talyst, a leader in ... American Society of Health-System Pharmacists (ASHP) Midyear Clinical ... access and secure management of CII medications. AutoVault ... restocking of controlled substance inventory. AutoVault ...
... The report " Active Pharmaceutical Ingredient (API) Market ... analyzes and studies the major market drivers, restraints, and opportunities ... Rest of the world. Browse market ... Pharmaceutical Ingredient (API) Market Trends, Competitive Landscape and Global Forecasts ...
Cached Medicine Technology:Talyst Unveils AutoVault™ at ASHP 2011 2MarketsandMarkets: API Market is Expected to Reach $159.08 Billion by 2016 2MarketsandMarkets: API Market is Expected to Reach $159.08 Billion by 2016 3
(Date:9/30/2014)... Irvine, Calif., Sept. 30, 2014 Research by UC ... system functions, shedding light on a vital process that ... , In the online version of Nature Immunology ... Zhou and other Institute for Immunology colleagues describe a ... and released into the bloodstream. , A T cell ...
(Date:9/30/2014)... University of Maryland-led research team has been awarded ... Institutes of Health (NIH) to develop new imaging ... our understanding of how large networks of neurons ... This knowledge will help researchers identify the precise ... behavior, like decision-making and speaking, and alterations in ...
(Date:9/30/2014)... September 30, 2014 EverStryke , the ... introduction to SurvivalLife.com along with a free book and class ... of Shane Michaels, prompting an investigative review. , “Joe ... in the survival and preparation niche, and this product is ... great classes and survival products that Joe offers on his ...
(Date:9/30/2014)... 2014 Elevate , the latest product ... in and out of the gym by providing natural ingredients ... attention of Shane Michaels, prompting an investigative review. , ... reason most people simply just don’t have the ability to ... at work, getting the motivation to finish a project, or ...
(Date:9/30/2014)... Los Angeles, CA (PRWEB) September 30, 2014 ... plastic surgery providers in Turkey has gone up more ... of growth. The medical tourism company also reported total ... since October 2012. , The company’s professional strategy has ... in Turkey — ultimately designed for patient comfort and ...
Breaking Medicine News(10 mins):Health News:UCI study uncovers important process for immune system development 2Health News:UMD receives inaugural BRAIN Initiative Award 2Health News:EverStryke: Review Exposes Joe Marshall’s Permanent Match Survival Product 2Health News:Elevate: Review Exposes Blue Star Nutraceutical’s Latest Supplement for Ultimate Brain Function, Focus, and Energy 2Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 2Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 3Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 4
... researchers have found that yo-yo dieting can more than double ... dieting, also known as weight cycling, is a repeated loss ... ,Researchers studied 140,057 women aged between 50 and ... yo-yo dieting and compared women average waist size to those ...
... have found that symptoms in patients with obstructive sleep ... with nasal insufflation (TNI), using a nasal cannula ... rate. ,Our findings provide evidence that TNI ... obstructive hypopneas and apneas, said lead researcher Hartmut Schneider, ...
... Patients with Chronic Obstructive Pulmonary Disease (COPD) are increasingly ... disease , but a new study finds that the ... be hospitalized for pneumonia. ,In a large ... inhaled corticosteroid use was associated with a significant 70 ...
... to open FatBurger fast food joint in Miami, Florida . ... South Beach diner revealed that she has been hooked to ... college. ,"That was part of my L.A. education ... all these low-riders (cars)... FatBurger was, like, the centrepiece for ...
... flowing in two of China's longest rivers -- the Yangtze ... change linked to the contraction of wetlands, warned the ... at the Chinese Academy of Sciences (CAS) as saying after ... wetlands on the Tibetan Plateau had shrunk by over 10 ...
... Actor/comedian Eddie Murphy is the worlds biggest love-rat, according to ... who has been named by Mel Bs pal Victoria Beckham ... callous way after she got pregnant with his child, topped ... Nutty Professor actor insisted on a DNA test to prove ...
Cached Medicine News:Health News:Nasal Cannula Treatment for Sleep Apnea Patients 2Health News:Nasal Cannula Treatment for Sleep Apnea Patients 3Health News:Patients Taking Inhaled Steroids may Develop Pneumonia 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: